Genome-wide meta-analysis reveals shared new <i>loci</i> in systemic seropositive rheumatic diseases.

Abstract

Immune-mediated inflammatory diseases (IMIDs) are heterogeneous and complex conditions with overlapping clinical symptoms and elevated familial aggregation, which suggests the existence of a shared genetic component. In order to identify this genetic background in a systematic fashion, we performed the first cross-disease genome-wide meta-analysis in systemic seropositive rheumatic diseases, namely, systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis and idiopathic inflammatory myopathies. We meta-analysed ~6.5 million single nucleotide polymorphisms in 11 678 cases and 19 704 non-affected controls of European descent populations. The functional roles of the associated variants were interrogated using publicly available databases. Our analysis revealed five shared genome-wide significant independent <i>loci</i> that had not been previously associated with these diseases: <i>NAB1</i>, <i>KPNA4-ARL14</i>, <i>DGQK</i>, <i>LIMK1</i> and <i>PRR12</i>. All of these <i>loci</i> are related with immune processes such as interferon and epidermal growth factor signalling, response to methotrexate, cytoskeleton dynamics and coagulation cascade. Remarkably, several of the associated <i>loci</i> are known key players in autoimmunity, which supports the validity of our results. All the associated variants showed significant functional enrichment in DNase hypersensitivity sites, chromatin states and histone marks in relevant immune cells, including shared expression quantitative trait <i>loci</i>. Additionally, our results were significantly enriched in drugs that are being tested for the treatment of the diseases under study. We have identified shared new risk <i>loci</i> with functional value across diseases and pinpoint new potential candidate <i>loci</i> that could be further investigated. Our results highlight the potential of drug repositioning among related systemic seropositive rheumatic IMIDs.